Learn how to Day Trade the Stock Market from a professional trader with over fifteen years of experience. My specialty is offering one-on-one tutoring to each of my students, and my favorite teaching tool is making videos of my trades so that you can see exactly how it's done. I've been teaching Day Trading for six years, and many of my students have become very successful traders. The Day Trading strategy I've perfected is very simple, and very easy to learn.
We're in the busiest weeks for earnings reports, and that can cause a lot of volatility to the indexes...As far as the recent move to the upside early last week, it was waaayyyyyy overdone and was nothing more than a suckers rally IMO...It was more like a Pump Before The DUMP...
Earnings can be (and are) manipulated, as you will see this coming week when many of the biggest banks/brokerage houses report...News for the overall economy continues to be very weak, and I'm still thinking we'll see 950 before we see 1250-1300 like some of the Elliot Wavers here on IHUB are calling for (chichi2)...Even Pretcher put out an article this past week calling for Dow 1000 (not a typo) over the next few years...
In my last two or three videos, I called for the Head & Shoulders chart pattern that's formed on the weekly chart to yield down to 950 or so, and if/when that happens, I'll get back to posting videos again...This chart pattern is still in effect IMO, and the fall to 950 (if it happens) will most likely not be straight down, but will have a few oversold rallies like we saw two weeks ago...The 50MA on the weekly chart is and will continue to be a major area of resistance IMO...
So for a while to come, I'll be enjoying the summertime and spending less time paying attention to the market...I am 100% cash except for a small position in one microcap biotech stock (CYCC), and I continue to accumulate physical gold and hide it in various places, in and out of the country...
Technical Analysis of the S&P 500's daily and weekly charts, plus a look at the important Economic and Earnings Reports due out next week...
This video is viewed best in Full-Screen Mode...Click the four arrows in the bottom right corner...Press the Escape key on your keyboard to exit back to Normal Mode...
Here is the end of the week Technical Analysis of the S&P 500's daily and weekly charts, plus a look at the important Economic and Earnings Reports due out next week...
Here is the end of the week Technical Analysis of the S&P 500's daily and weekly charts, plus a look at the important Economic and Earnings Reports due out next week...
Every Sunday evening, I post a video here and on a few other sites that shows the technical analysis of the $SPX daily and weekly charts. I also show the Dow Jones Industrial Average, the Nasdaq Composite, and the Russell 2000 charts, and talk about what kinds of news, earnings reports, and economic reports to pay attention to in the coming week.
The FDA staff said it has a bunch of questions about InterMune’s new drug to slow deteriorating lung functioning. But investors figure the concerns weren’t as bad as they could have been, sending the biotech’s shares soaring.
The stock jumped as much as 74% after FDA reviewers said only one of InterMune’s two late-stage trails for the experimental drug pirfenidone had met its main goal and added that “the clinical significance of the treatment effect size is uncertain.”
The FDA documents, which were released ahead of an advisory panel meeting to discuss the drug Tuesday March 9th, also had a mix of other things to say.
All things considered, an Oppenheimer analyst noted the “tone was less negative than expected,” all things considered and there was room for the drug to still get FDA approval. The shares settled down in later trading, but still finished up nearly 60% for the day.
InterMune often appears on lists of likely biotech takeover candidates. FDA approval of pirfenidone would give it two drugs on the U.S. market.
The new drug would treat idiopathic pulmonary fibrosis, which affects about 200,000 Americans, the majority of whom eventually die of respiratory failure. The FDA noted that there aren’t any approved drugs to treat IPF, although drugs like corticosteroids and drugs that suppress the immune system are used, according to Dow Jones Newswires.
The company also put out material noting that “the slowing of progression in loss of lung volume constitutes a clear benefit to patients,” Reuters said.
Here’s more news that came out on Friday about ITMN:
Look at the difference in the numbers shown by the Yahoo Finance and the Finviz.com sites. Notice the differences between the Float numbers, the percentage of shares owned by Institutions, and the percentage of shares owned by Insiders. There is also a large difference in the number and the percentage of shares that are Short.
That's probably due to when each site updates their data. I usually prefer to get my information from Yahoo Finance, because they usually update their data faster than Finviz.com does.
I read on the IHUB message board that Insiders recently purchased 30 million shares, but I haven't been able to verify that yet. That may account for the differences between the Yahoo Finance and the Finviz.com information.
The Yahoo Finance numbers:
The Finviz.com numbers:
Look at all of the Insider Transactions for January 26th, 2010. Insiders started buying again on that date, which is a vote of confidence from the people that run this company:
But here, Yahoo Finance missed Oppenheimer's reiteration of an Outperform rating on January 25th, 2010.
Yahoo Finance:
Finviz.com:
Here is an hourly, daily, and a weekly chart of ITMN. There is a short YouTube video below these chartrs that shows Technical Analysis of these charts.
Here is the Option Chain for ITMN as of the close on Friday March 5th, 2010. These Options expire on the third Friday in March, which is March 19th, 2010:
Here's a nine minute YouTube video that analyzes ITMN's charts:
Someone requested that I do an analysis of the stock JASO.
This short ten minute video shows how I do Fundamental Analysis and Technical Analysis of the daily and weekly charts of JA Solar Holdings, which is a company based in Shanghai China and trades in the U.S. on the Nasdaq exchange under the ticker symbol JASO.
About JA Solar Holdings:
JA Solar Holdings Co. Ltd. through its subsidiaries, engages in the design, manufacture, and marketing of high-performance solar cells. It offers monocrystalline and multicrystalline solar cells. The company sells its products to solar module manufacturers who assemble and integrate solar cells into modules and systems that convert sunlight into electricity for power generation. JA Solar Holdings Co., Ltd. has operations in the People’s Republic of China, Spain, and rest of the world. The company was founded in 2005 and is based in Shanghai, the People’s Republic of China.
Disclaimer: I am not a licensed broker, and everything I say in this video is for educational purposes only. In no way am I making a recommendation to Buy, Hold, or Sell this stock.
This is the third weekend I've done the end of the week Fundamental and Technical Analysis of ANX's daily and weekly charts...
We are expecting news in the very near future that will tell us if the FDA has accepted the NDA (new drug application) for their drug candidate ANX-530
Things are about to get VERY interesting with this stock in the next week or two...Stay tuned for recent developments as they happen...
Disclaimer: I hold a lot of shares of ANX, and am VERY Bullish on this company...GLTA
We only have to wait two weeks or less before we hear if the NDA for ANX-530 will be accepted by the FDA...That news WILL determine the next move for this stock...Either up or down...Volume should pick up again once this news is released...
This video is viewed best at 480p and full-screen mode...Start the video, click on 480p in the lower right corner, then click the four arrows pointing different direction to go to full-screen mode...Press the Escape key on your keyboard to exit full-screen mode...
Posts
